Closed · EP-IDS-16-001 · CFDA 93.360 · Discretionary
Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator
Federal grant opportunity posted by Assistant Secretary for Preparedness and Response, cataloged on Grants.gov.
- $30M-$30M
- Award range
- Closed
- Status
- April 15, 2016
- Close date
- 1
- Expected awards
The verdict
Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator is a closed discretionary listing from Assistant Secretary for Preparedness and Response that offered $30,000,000 -- $30,000,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 66 other opportunities from Assistant Secretary for Preparedness and Response.
- $30M-$30M
- award range
- Closed
- application status
- 1
- expected award
- 93.360
- CFDA program
Archived opportunity record
Combating Antibiotic Resistant Bacteria is closed (last close April 15, 2016). Check the agency catalog for replacement NOFOs. Assistant Secretary for Preparedness and Response still indexes 66 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed April 15, 2016
Est. Total Funding
$250,000,000
Expected Awards
1
Instrument
Cooperative Agreement
Description
The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.
Market-open applicant set · includes for-profit door
The eligibility set for Combating Antibiotic Resistant Bacteria includes a for-profit door among 6 printed types (Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Private institutions of higher education; For-profit organizations other than small businesses; +2 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Science and Technology / R&D (ST). Inside Assistant Secretary for Preparedness and Response's indexed book this exact eligibility-code string is unique to this listing.
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
Grants.gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. support@grants.gov
More from Assistant Secretary for Preparedness and Response
What to do next
Combating Antibiotic Resistant Bacteria is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.360 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |